- Records
- 19
- Recruiting
- 11
- Recruiting sites
- 613
- Countries
- 18
Peptide trials,
without the maze.
Search every official registry record matched to 13 tracked peptide and next-generation weight-loss programs. Find current status, phase, enrollment, countries, US states, recruiting cities, postal areas, completion timing, and the direct NCT source.
Study status is not drug rank.
Bar length shows registry-listed sites individually marked Recruiting. Larger programs can create larger counts. This does not compare efficacy, safety, approval odds, sponsor quality, or enrollment availability.
- Records
- 52
- Recruiting
- 10
- Recruiting sites
- 170
- Countries
- 7
- Records
- 37
- Recruiting
- 10
- Recruiting sites
- 73
- Countries
- 3
- Records
- 24
- Recruiting
- 10
- Recruiting sites
- 935
- Countries
- 28
- Records
- 27
- Recruiting
- 6
- Recruiting sites
- 1,581
- Countries
- 36
- Records
- 30
- Recruiting
- 5
- Recruiting sites
- 155
- Countries
- 6
- Records
- 8
- Recruiting
- 4
- Recruiting sites
- 339
- Countries
- 23
- Records
- 31
- Recruiting
- 3
- Recruiting sites
- 774
- Countries
- 34
- Records
- 15
- Recruiting
- 3
- Recruiting sites
- 3
- Countries
- 1
- Records
- 34
- Recruiting
- 2
- Recruiting sites
- 450
- Countries
- 27
- Records
- 9
- Recruiting
- 2
- Recruiting sites
- 4
- Countries
- 3
- Records
- 9
- Recruiting
- 1
- Recruiting sites
- 8
- Countries
- 1
- Records
- 5
- Recruiting
- 0
- Recruiting sites
- 0
- Countries
- 0
Filter the exact records.
Search names, former codes, NCT IDs, sponsors, interventions, conditions, cities, and postal codes. Filtered URLs are shareable but intentionally excluded from search indexing so this page remains the canonical source.
| Program and record | Status | Phase and enrollment | Locations | Primary completion | Registry update | Source |
|---|---|---|---|---|---|---|
| RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)NCT07009860 / Altimmune, Inc. | RecruitingVerified 2026-03 | Phase 2100 estimated | 8 recruiting43 listed / 2 countries | Mar 31, 2027estimated | Mar 20, 2026ClinicalTrials.gov | Open NCT07009860 ↗ |
| RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or OverweightNCT06987513 / Altimmune, Inc. | Active, not recruitingVerified 2025-11 | Phase 2100 actual | 0 recruiting12 listed / 1 countries | May 2026estimated | Nov 19, 2025ClinicalTrials.gov | Open NCT06987513 ↗ |
| ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and TolerabilityNCT04561245 / Altimmune, Inc. | CompletedVerified 2025-06 | Phase 1100 actual | 0 recruiting1 listed / 1 countries | Oct 29, 2021actual | Jun 24, 2025ClinicalTrials.gov | Open NCT04561245 ↗ |
| Pemvidutide (ALT-801) DDI Study in Healthy VolunteersNCT04972396 / Altimmune, Inc. | CompletedVerified 2025-06 | Phase 140 actual | 0 recruiting2 listed / 1 countries | May 15, 2022actual | Jun 24, 2025ClinicalTrials.gov | Open NCT04972396 ↗ |
| ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)NCT05006885 / Altimmune, Inc. | CompletedVerified 2023-07 | Phase 195 actual | 0 recruiting15 listed / 1 countries | Aug 17, 2022actual | Jul 27, 2023ClinicalTrials.gov | Open NCT05006885 ↗ |
| ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)NCT05134662 / Altimmune, Inc. | CompletedVerified 2025-06 | Phase 155 actual | 0 recruiting7 listed / 1 countries | Feb 3, 2023actual | Jun 24, 2025ClinicalTrials.gov | Open NCT05134662 ↗ |
| Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)NCT05292911 / Altimmune, Inc. | CompletedVerified 2022-10 | Phase 164 actual | 0 recruiting13 listed / 1 countries | Oct 31, 2022actual | Jul 27, 2023ClinicalTrials.gov | Open NCT05292911 ↗ |
| Efficacy and Safety of ALT-801 in the Treatment of ObesityNCT05295875 / Altimmune, Inc. | CompletedVerified 2023-11 | Phase 2391 actual | 0 recruiting31 listed / 1 countries | Sep 28, 2023actual | Nov 29, 2023ClinicalTrials.gov | Open NCT05295875 ↗ |
| IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)NCT05989711 / IMPACT / Altimmune, Inc. | CompletedVerified 2026-05 | Phase 2212 actual | 0 recruiting40 listed / 3 countries | Nov 25, 2025actual | May 18, 2026ClinicalTrials.gov | Open NCT05989711 ↗ |
Country and US state routes.
Counts are site observations across registry records, not unique facilities. The same research center can appear in multiple studies. Open the exact NCT record before treating a location as current.
Status, location, and enrollment are different fields.
These answers prevent the most common registry-search errors before a reader follows an official source.
Are any Retatrutide clinical trials recruiting?
Yes. This 2026-07-24 snapshot contains 2 Retatrutide registry records with an overall Recruiting status and 450 listed sites individually marked Recruiting. Overall status does not mean every site is open, and neither status establishes eligibility or enrollment. Open the exact NCT record and verify the individual location before contacting a study team.
How do I find a peptide clinical trial near me?
Enter a city or postal code, optionally add a country or US state, and then open the exact ClinicalTrials.gov record. This finder retains location rows individually marked Recruiting but omits facility and personal contact fields. Confirm current recruitment, eligibility, official contact route, and travel requirements on the registry. Peptide Local does not enroll participants.
Does Recruiting mean I can join the trial?
No. Recruiting is a registry status, not an eligibility decision or appointment. A study can be recruiting overall while some listed locations are not yet recruiting, active but closed, completed, suspended, or missing a current site status. The study team applies the protocol's eligibility and consent process.
Are the drugs in this clinical trial finder FDA approved?
A ClinicalTrials.gov record is not FDA approval. The finder covers investigational programs and can also include studies involving components or comparators with separate regulatory histories. Approval must be verified on the exact FDA label or regulator record, not inferred from a phase, sponsor, trial result, or recruiting status.
Why do only some registry records show posted results?
11 of 268 records in this snapshot expose a ClinicalTrials.gov results module. A record without posted registry results can still have a publication or sponsor announcement elsewhere, while a posted module still requires careful interpretation. Results availability is not a quality rank.
How current is the peptide clinical trial data?
The registry data timestamp is July 24, 2026 at 9:00 AM UTC. The refresh workflow searches exact intervention names and aliases, deduplicates by NCT ID, preserves multi-program studies, and stores overall and individual-site status separately. Registry fields can change after that timestamp, so the direct source remains authoritative for enrollment decisions.
A registry finder, not an enrollment service.
A dated transformation of ClinicalTrials.gov intervention-search records for thirteen named Peptide Local pipeline programs. Study sponsors or investigators submit and maintain registry records. Overall status, individual-site status, enrollment, locations, completion dates, and results availability can change. Recruiting status does not establish eligibility, enrollment, treatment access, regulatory approval, routine availability, or a favorable benefit-risk conclusion.
Peptide Local omits personal contact details and does not screen participants, recommend a protocol, interpret eligibility, arrange treatment, or authenticate commercial products that reuse an investigational program's name.
Read the official API documentation ↗Understand evidence categories →